25,729 articles
David G. Hoel
David G. Hoel is an American biostatistician and environmental epidemiologist, a Distinguished University Professor at the Medical University of South Carolina and National Academy of Medicine member.
David Goggins
David Goggins, also known as Dave Goggins, is an American retired Navy SEAL, ultramarathon runner, and author known for extreme endurance feats and his 2018 memoir Can't Hurt Me.
David Heymann (epidemiologist)
David Heymann is an infectious disease epidemiologist and professor at the London School of Hygiene & Tropical Medicine who led the World Health Organization's 2003 SARS response.
David Jonathan Casarett
David Jonathan Casarett is an American physician-scientist in hospice and palliative medicine who leads palliative care at Duke University and created the Measuring What Matters quality indicators.
David Korn (pathologist)
David Korn (1933–2024) was an American pathologist and research-policy leader who was dean of the Stanford School of Medicine and Harvard's inaugural vice provost for research.
David L. Katz
David L. Katz, American physician and nutrition researcher; founder of Yale-Griffin Prevention Research Center, True Health Initiative, and Diet ID; past president of the American College of Lifestyle Medicine.
David Laid
David Laid, Estonian-American fitness influencer and Gymshark Creative Director of Lifting, famous for his viral 3 Year Natural Transformation 14-17 video; his natural status is unverified and debated (FFMI about 22.4).
David M. Carlisle
David M. Carlisle is an American physician and health services researcher who has served as President and CEO of Charles R. Drew University of Medicine and Science in Los Angeles since 2011.
David M. Lawrence
David M. Lawrence is an American physician-executive, board certified in preventive medicine, who led Kaiser Foundation Health Plan and Hospitals as CEO and chairman from 1991 to 2002.
David Meyers
David Meyers was an American family physician and health services researcher who served as Deputy Director of the Agency for Healthcare Research and Quality until his death in 2023.
David Nutt
David Nutt, British neuropsychopharmacologist at Imperial College London, creator of the Lancet drug-harm rankings (alcohol most harmful), sacked as UK ACMD chair in 2009, founder of Drug Science and GABA Labs.
David R. Challoner
David R. Challoner is an American physician-executive who served as vice president for health affairs at the University of Florida from 1982 to 1998, growing Shands into an eight-hospital system.
David Reimer
David Reimer (Bruce Reimer, 1965-2004), Canadian man of the John/Joan case: reassigned female as an infant by John Money after a botched circumcision, rejected the identity, reverted to male, and became evidence against nurture-only gender theory.
David S. Wilkes
David S. Wilkes is an American pulmonary physician-scientist known for establishing autoimmunity's role in lung transplant rejection and dean of the University of Virginia School of Medicine from 2015 to 2021.
David Sheff
David Sheff, American journalist and author of Beautiful Boy (2007), the memoir of son Nic Sheff's meth addiction, and Clean (2013); also known for the 1980 Playboy interview with John Lennon and Yoko Ono and the 2025 biography Yoko.
David V. Schaffer
David V. Schaffer is an American bioengineer at the University of California, Berkeley, elected to the National Academy of Engineering for his work on viral gene therapy vectors.
David Vetter
David Phillip Vetter, the "Bubble Boy" (1971–1984), was an American boy with X-linked SCID who lived twelve years in sterile plastic isolators, received a 1983 sister-donor marrow transplant, and died at 12; his cells later identified the SCID gene.
David Zhang
David Yu Zhang is an American bioengineer known for nucleic acid diagnostics and liquid biopsy for cancer; formerly a Rice University professor, he received a PECASE award in 2019.
Dawn Jackson Blatner
Dawn Jackson "DJ" Blatner is a Chicago-based registered dietitian nutritionist (RDN, CSSD), creator of the flexitarian diet, author of The Flexitarian Diet and The Superfood Swap, winner of ABC's My Diet Is Better Than Yours, and former Chicago Cubs head dietitian.
Daylight photodynamic therapy
Daylight photodynamic therapy (DL-PDT, also dPDT) is a dermatological treatment in which a photosensitizing cream is activated by daylight to treat actinic keratoses, nearly painlessly.
Dayuan Yin
达原饮 (Dayuan Yin, Membrane-source Decoction) is a seven-herb Chinese medicine formula from Wu Youxing's 1642 Wenyi Lun for pestilence with pathogen hidden in the membrane source; used for fevers, SARS and COVID-19 research.
Dazdotuftide
Dazdotuftide (TRS01) is a steroid-free small-molecule immunomodulator eye drop from Tarsier Pharma, a tuftsin-phosphorylcholine conjugate in phase 3 development for non-infectious anterior uveitis, distinguished by superior intraocular pressure safety versus prednisolone acetate.
Dazodalibep
Dazodalibep (VIB4920, HZN4920, AMG 611) is an investigational CD40 ligand antagonist for Sjögren's disease, originally developed by MedImmune and now developed by Amgen.
Dazukibart
Dazukibart (PF-06823859), Pfizer's humanized IgG1 monoclonal antibody neutralizing interferon-beta; investigational biologic in Phase 3 for dermatomyositis and Phase 2 for lupus, with strong Phase 2 skin efficacy data.
DB-1324
DB-1324 is a CDH17-targeting antibody-drug conjugate from Duality Biologics' DITAC platform, optioned to GSK in December 2024 for up to $975 million in milestones, now in a Phase 1/2 first-in-human gastrointestinal tumor trial.
DB-1418, EGFR/HER3 bispecific antibody-drug conjugate
DB-1418 (AVZO-1418) is DualityBio's EGFR/HER3 bispecific antibody-drug conjugate with a topoisomerase I inhibitor payload (DAR 6), licensed to Avenzo Therapeutics ex-Greater China, in the AVENTINE-1 Phase 1/2 trial with FDA Fast Track for EGFR-mutant TKI-pretreated NSCLC.
DBAR study
DBAR study: Diamond Blackfan Anemia Registry of North America (NCT00106015), a Northwell Health patient registry since 1991 with over 850 DBA patients, known for quantifying elevated cancer risk in DBA.
Dbpr-108
DBPR108 (prusogliptin) is a once-daily DPP-4 inhibitor for type 2 diabetes, developed by Taiwan's NHRI and approved by China's NMPA in January 2025; phase 3 trials showed HbA1c reductions of about 0.6-0.7%, non-inferior to sitagliptin.
dC-dT-MDS trial
dC-dT-MDS trial (DC-DT-MDS022021): phase 2 single-arm McGill University Health Centre trial of deoxycytidine/deoxythymidine for mitochondrial DNA depletion disorders, including POLG-related disease, with improved NMDS scores and lower GDF-15.
DCIS trial
DCIS trial (NCT03002766): Milan phase 2 prospective study of 224 women testing a margin-width plus risk-factor score to omit radiotherapy after breast-conserving surgery for ductal carcinoma in situ; 1.138% yearly recurrence with 57.6% avoiding radiation.